Benzinga | Aug 10, 2020 08:30AM EDT

Cellectar Biosciences Q2 EPS $(0.26) Beats $(0.30) Estimate

Cellectar Biosciences (NASDAQ:CLRB) reported quarterly losses of $(0.26) per share which beat the analyst consensus estimate of $(0.30) by 13.33 percent. This is a 43.48 percent increase over losses of $(0.46) per share from the same period last year.